Digital Biomarkers in Parkinson’s Disease Trials (2015–2025)

Concise, data-backed market intelligence report for pharma, CROs, and medtech teams

Digital biomarkers are extremely promising in Parkinson’s disease—but many questions remain unanswered for industry:
- Significant regulatory uncertainty: FDA and EMA acknowledge digital endpoints, but it is unclear which will gain traction.
- Dozens of devices and protocols are being proposed - which are the ones the sponsors are actually testing?
- Gait and accelerometry dominate the literature - are sleep, cognition, speech/voice, ocular metrics really making it into trials?This 15-page report answers those questions by analyzing 89 Parkinson’s trials (2015–2025) that actually deployed digital endpoints.
Why you should get it:
- Save Time – We scan ClinicalTrials.gov, PubMed, and FDA updates so you don’t have to.
- Stay Ahead – Spot competitors, track regulatory signals, and monitor adoption trends.
- Improve decision making – Concise, structured, and actionable insights tailored for pharma & CRO professional.

Report Spotlight

The report analyzed 89 Parkinson’s trials (2015–2025) that actually deployed digital endpoints.
- *Adoption Trend (2015→2025): steady early activity, spike in 2019, pandemic dip in 2020, then sustained recovery 2022–2025.
- Study Type Reality: 23 interventional (26%) vs 66 observational (74%) — a clear view of where endpoints are progressing beyond feasibility.
- Endpoints in Use (appearance counts): accelerometry (64), gait (31), smartphone/tapping (20); non-motor signals are emerging — cognition (16), sleep (8), speech/voice (4), ocular (3), ECG/HRV (3).
- Who’s Leading: Adoption led by academic & device partners; top sponsors include Radboud UMC, Shirley Ryan AbilityLab, Great Lakes NeuroTechnologies.
- Regulatory Signals: Highlights Parkinson’s trials that use digital endpoints flagged in FDA and EMA discussions. Tracks which measures remain exploratory and which are advancing into secondary or primary outcomes.
- Appendix: Complete list of all 89 trials with NCT IDs, sponsors, endpoints, status, and dates.

About Us

Digital Biomarker Brief was founded to help decision-makers cut through the noise in a rapidly evolving field. We believe busy professionals shouldn’t need to scan hundreds of trials, papers, and regulatory releases to understand where digital biomarkers are headed. Our mission is to provide trusted, data-backed intelligence — both concise and deep enough to support strategic planning.